心力衰竭患者血中生长激素水平的研究

目的研究心力衰竭患者血中生长激素(GH)和胰岛素样生长因子(IGF)-1水平。方法选择心力衰竭患者56例和正常对照者30名,使用Immulite全自动化学发光免疫分析仪,用化学发光免疫分析方法测定GH,使用Gamma-C12计数仪,用免疫放射分析方法测定IGF-1。结果心力衰竭患者血中GH和IGF-1水平均低于正常对照组(P<0.01和P<0.05)。心力衰竭患者血中GH和IGF-1水平呈正相关关系(r=0.676,P<0.05)。不同程度心力衰竭患者血中GH和IGF-1水平不同,心功能Ⅲ级组低于心功能Ⅱ级组(P<0.05和P<0.05),心功能Ⅳ级组低于心功能Ⅱ级组(P<0.01和P<0.05),而心功能Ⅲ级组与心功能Ⅳ级组之间差异无显著性(P均>0.05)。不同疾病引起的心力衰竭患者血中GH和IGF-1水平与相应的对照组比较,扩张型心肌病组明显低于对照组(P均<0.01),缺血性心肌病组低于对照组(P<0.01和P<0.05),高血压心脏病组GH低于对照组(P<0.05),IGF-1与对照组的差异无显著性(P>0.05),风湿性心脏病组均低于对照组(P均<0.05)。结论心力衰竭患者血中GH和IGF-1水平降低,并且两者呈正相关关系。不同程度心力衰竭患者血中GH和IGF-1水平不同,心力衰竭程度重者(心功能Ⅲ级和Ⅳ级组)较心力衰竭程度轻者(心功能Ⅱ级组)低。扩张型心肌病和缺血性心肌病引起的心力衰竭患者血中GH和IGF-1水平

A study on levels of growth hormone in patients with heart failure

Objective To study the levels of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) in patients with heart failure. Methods GH and IGF-1 were measured in 56 patients with heart failure and 30 normal control people by chemiluminescence immunoassay and immunoradiometric assay, respectively. Results Compared with in normal control group, GH and IGF-1 decreased significantly in all patients with heart failure (P<0.01 and P<0.05). GH level was positively relevant to IGF-1 level in patients with heart failure (r=0.676, P<0.05). GH and IGF-1 in cardiac function grade Ⅲ and grade Ⅳ were lower than those in cardiac function grade Ⅱ(P<0.05 and P<0.05, P<0.01 and P<0.05). There were no significant differences in the levels of GH and IGF-1 between cardiac function grade Ⅲ and grade Ⅳ. Compared with controls, GH and IGF-1 in dilated cardiomyopathy group and ischemic cardiomyopathy group decreased significantly (P<0.01, P<0.01 and P<0.05 respectively). GH in hypertension group decreased significantly (P<0.05). No difference in IGF-1 was found in hypertension group (P>0.05). GH and IGF-1 in rheumatic heart disease group decreased significantly (P<0.05 and P<0.05). Conclusion The levels of GH and IGF-1 decreased in patients with heart failure. GH level was positively relevant to IGF-1 level. GH and IGF-1 were decreased remarkably in patients with serious heart failure (cardiac function grade Ⅲ and Ⅳ) in both the dilated cardiomyopathy group and the ischemic cardiomyopathy group.